Hemogenyx Pharmaceuticals Plc (LON:HEMO)

London flag London · Delayed Price · Currency is GBP · Price in GBX
317.50
+14.00 (4.61%)
Feb 21, 2025, 5:07 PM BST
-74.64%
Market Cap 11.44M
Revenue (ttm) n/a
Net Income (ttm) -5.18M
Shares Out 3.60M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,907
Average Volume 18,190
Open 306.99
Previous Close 303.50
Day's Range 303.60 - 320.00
52-Week Range 270.00 - 1,276.00
Beta 3.24
RSI 38.78
Earnings Date Apr 25, 2025

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hema... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 17
Stock Exchange London Stock Exchange
Ticker Symbol HEMO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.